Achondroplasia, the most common form of dwarfism, has had a treatment breakthrough in recent years — but every approved therapy for it is an injection, daily or weekly, given to children. A Phase III trial published in the New England Journal of Medicine now points at a pill.
PROPEL 3 enrolled 114 children and adolescents aged 3 to 17 at 27 sites in 10 countries, randomising them to daily oral infigratinib or placebo for 52 weeks. The study met its primary endpoint. Children on the drug reached an annualised growth velocity of 5.96 cm per year, against 4.22 cm per year on placebo — a difference of 1.74 cm per year. Height z-scores, which measure growth against what is expected in achondroplasia, improved too.
The mechanism is a repurposing story. Achondroplasia is caused by gain-of-function variants in FGFR3, a receptor that regulates bone growth; too much signalling slows the growth plates. Infigratinib was developed to inhibit FGFR signalling in cancer. Researchers reasoned that the same inhibition, aimed at a different disease for a different reason, might loosen the brake on bone.
There was also a signal on proportions, not just height. The trial's overall measure of upper-to-lower body segment ratio did not reach statistical significance, but the effect appeared stronger in children aged 3 to under 8 — a hint that the drug may influence how bone grows, not only how fast. "These results suggest an oral therapy may be as effective or more effective than current injectable therapies," said Benjamin Cocanougher of Cincinnati Children's, an investigator at one of the sites.
Tolerability looked acceptable: adverse events occurred at similar rates in both arms and no serious adverse events were judged related to the drug.
The caveats are the usual ones for a first Phase III, and they weigh heavily here. Fifty-two weeks is a short window in a condition managed across a childhood. Adult height, quality of life and — crucially — the complications that make achondroplasia more than a question of stature, such as foramen magnum stenosis requiring neurosurgery, are not answered by a year of growth data. An extension study is running.
The regulatory clock is already ticking: BridgeBio, which funded the trial, has a PDUFA date of February 4, 2027. If approved, infigratinib would be the first oral therapy for the condition — a change that sounds cosmetic and is not. Daily injections shape a childhood: school days, travel, the ritual of a needle. A pill changes the arithmetic of who can be treated, where, and for how long.
What to watch: the February decision, the extension data on proportions and complications, and pricing — an oral chronic therapy for a rare disease will have to justify itself against injectables that already exist.
